Life Sciences Tools and Services

Bio-Rad Lab-B

Elliott Increases Stake in Life Science Tools Supplier Bio-Rad

Bio-Rad Lab-B released FY2026 Q1 earnings on April 30 After-Market (EST), actual revenue USD 592.1 M (forecast USD 588.86 M), actual EPS USD -19.5526

Bio-Rad Lab-B to Release FY2026 Q1 Earnings on April 30 After-Market EST, Forecast Revenue USD 588.86 M

Bio-Rad Lab-B released FY2025 earnings on February 13 After-Market EST, actual revenue USD 2.583 B (forecast USD 2.575 B), actual EPS USD 27.85

Bio-Rad Lab-B released FY2025 Q4 earnings on February 13 After-Market EST, actual revenue USD 693.2 M (forecast USD 687.71 M), actual EPS USD 26.648

Bio-Rad Lab-B to Release FY2025 Q4 Earnings on February 12 After-Market EST, Forecast Revenue USD 694.64 M

Bio-Rad Lab-B released FY2025 Q3 earnings on October 29 After-Market EST, actual revenue USD 653 M (forecast USD 652.58 M), actual EPS USD -12.7

Bio-Rad Lab-B released FY2025 9 Months earnings on October 29 After-Market (EST), actual revenue USD 1.89 B, actual EPS USD 1.26

Bio-Rad Lab-B to Release FY2025 Q3 Earnings on October 29 After-Market EST, Forecast Revenue USD 651.3 M

Bio-Rad Lab-B released FY2025 Q2 earnings on July 31 After-Market EST, actual revenue USD 0 (forecast USD 614.29 M), actual EPS USD 0

Bio-Rad Lab-B released FY2025 Semi-Annual earnings on July 31 After-Market (EST), actual revenue USD 1.237 B, actual EPS USD 13.8364

Bio-Rad Lab-B to Release FY2025 Q2 Earnings on July 31 After-Market (EST), Forecast Revenue USD 614.29 M

Bio-Rad Labs Reports Quarterly Earnings Per Share of $2.54

Bio-Rad Lab-B released FY2025 Q1 earnings on May 1 After-Market EST, actual revenue USD 585.4 M (forecast USD 573.23 M), actual EPS USD 2.29

Bio-Rad Laboratories-B Reports Q1 2025 Financials

Bio-Rad Lab-B to release FY2025 Q1 earnings on May 1 After-Market EST, forecast revenue USD 573.23 M

Bio-Rad Lab-B released FY2024 Q4 earnings on February 13 After-Market EST, actual revenue USD 667.5 M (forecast USD 679.75 M), actual EPS USD -25.567

Bio-Rad Lab-B released FY2024 annual earnings on February 13 After-Market (EST), actual revenue 2.567 B USD (forecast 2.581 B USD), actual EPS -65.3647 USD

Bio-Rad Lab-B to Release FY2024 Q4 Earnings on February 13, After-Market EST; Forecasted Revenue: 679.75 M USD

Bio-Rad Lab-B released FY2024 9 Months Earnings on October 30 After-Market EST, actual revenue USD 1.899 B, actual EPS USD -39.4729

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Silexion Therapeutics

Micware

GCL Global

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

MetaVia

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

BIO.B

TESL

TSLT

TSLR

TSLL

TSLG

Elliott Management has acquired a significant stake in Bio-Rad, a life-science tools supplier. Budget airlines are taking over Spirit's routes and slots. NextEra Energy is nearing a deal for Dominion. Tesla raised prices on some Model Y trims. Walmart and Target are adapting to changing shopping habits due to rising gas prices. Federal prosecutors are investigating BlackRock's private-credit fund. SpaceX plans to go public, and Mercedes-Benz is open to defense production.

MorningStar

GraniteShares 1.25 Long TSLA Daily ETF

Bio-Rad Lab

Simplify Volt TSLA Revolution ETF

T-Rex 2X Long Tesla Daily Target ETF

GraniteShares 2x Long TSLA Daily ETF

Direxion Daily TSLA Bull 2X Shares

Leverage Shares 2X Long TSLA Daily ETF

Allegiant Travel

Frontier

Nextera Energy

Dominion Energy

Tesla

Walmart

Target

OpenAI

BlackRock

TCP Capital

Amgen

Kissei Pharmaceutical Co., Ltd.

Berkshire Hathaway

Berkshire Hathaway B

Delta Air Lines

Amazon

Mastercard

Visa

Unitedhealth

Deere

Microsoft

NEXTERA ENERGY CAPITAL HLDGS INC 5.65%JNR SUBORD DEB 01/03/2079 SER N

NEXTERA ENERGY CAPITAL HLDGS INC 6.5% BDS 15/04/86 USD1000

Nextera Energy Partners LP

NEXTERA ENERGY INC 6.926% CORPORATE UNITS 01/09/2025

NEXTERA ENERGY INC CORP UNIT 01/11/2029

NEXTERA ENERGY CAPITAL HLDGS INC 6.5% BDS 01/06/85 USD25

NEXTERA ENERGY INC CORP UNIT 01/06/2027

NEXTERA ENERGY INC CORP UNIT

BlackRock Tech and Private Equity Term Trust

BLACKROCK MULTI-SECTOR INCOME TR COM USD0.001(S/R 09/09/2025) WI

Blackrock Enhanced Div Achievers Trust

BlackRock Science and Tech Term Trust

BlackRock Multi-Sector Income Trust

Dow Jones Top Company Headlines at 9 PM ET: Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad | Rival ...

Bio-Rad Laboratories (NYSE:BIO.B) experienced a 27% increase in trading volume, with 380 shares traded on Friday. The stock price fell by 1.1% to $255.54, down from a previous close of $258.46. The company has a market cap of $6.90 billion, a PE ratio of 42.10, and a net margin of 6.52%. Analysts currently rate Bio-Rad as a Hold, but suggest other stocks may be better investment options.

Market Beat

Bio-Rad Laboratories (NYSE:BIO.B) Sees Strong Trading Volume  - Should You Buy?

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) announced its participation in two upcoming investor conferences. The first is the RBC Capital Markets Global Healthcare Conference on May 19, 2026, featuring CFO Roop K. Lakkaraju. The second is the Jefferies 2026 Global Healthcare Conference on June 3, 2026, also with CFO Lakkaraju. Both events will include fireside chats and one-on-one meetings, with webcasts available on Bio-Rad's Investor Relations website.

StockTitan

ROYAL BANK OF CANADA

Jefferies Financial

Bio-Rad to Participate in Upcoming Investor Conferences | BIO Stock News

Bio-Rad Laboratories (NYSE:BIO.B) reported quarterly earnings of $1.89 per share, with a net margin of 29.42% and a return on equity of 3.86%. The stock traded up $22.45 to $299.45, with a market cap of $8.08 billion. The company operates in life sciences and clinical diagnostics, providing innovative products and systems. Analysts currently rate the stock as a Hold, but suggest other stocks may be better investments.

Bio-Rad Laboratories (NYSE:BIO.B) Posts Earnings Results

Bio-Rad Laboratories (NYSE:BIO) is set to release its Q1 2026 earnings on April 30, after market close. Analysts predict earnings of $1.97 per share and revenue of approximately $589.89 million. The company previously reported Q4 earnings of $2.51 per share, missing estimates. Bio-Rad's stock opened at $300.64, with a market cap of $8.11 billion. Institutional investors hold 65.24% of the stock, and recent analyst ratings show a mix of buy, hold, and sell recommendations, with an average rating of "Hold" and a price target of $339.75.

Bio-Rad Laboratories (BIO) to Release Quarterly Earnings on Thursday

GBIO

IBBQ

LABU

Anthropic has acquired biotech startup Coefficient Bio for $400 million in stock. This acquisition aligns with Anthropic's expansion into healthcare, following the launch of its Claude for Life Sciences tool. Coefficient Bio, founded by Samuel Stanton and Nathan C. Frey, focuses on using AI to enhance drug discovery and biological research efficiency. The startup's team of about 10 will integrate into Anthropic's health and life science division.

TechCrunch

SPDR S&P Biotech

iShares Biotechnology ETF

Generation Bio

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Anthropic buys biotech startup Coefficient Bio in $400M deal: reports

Bio-Rad Lab-B(BIO.B.US)

Dow Jones Top Company Headlines at 9 PM ET: Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad | Rival ...

Bio-Rad Laboratories (NYSE:BIO.B) Sees Strong Trading Volume - Should You Buy?

Bio-Rad to Participate in Upcoming Investor Conferences | BIO Stock News

Bio-Rad Laboratories (NYSE:BIO.B) Posts Earnings Results

Bio-Rad Laboratories (BIO) to Release Quarterly Earnings on Thursday

Anthropic buys biotech startup Coefficient Bio in $400M deal: reports